Results 71 to 80 of about 33,911 (221)

Reversible cerebral vasoconstriction syndrome: A narrative review

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1162-1180, May 2026.
Abstract Objectives/Background This review summarizes current insights into Reversible cerebral vasoconstriction syndrome (RCVS) diagnosis, management, and outcomes. RCVS is a cerebrovascular disorder characterized by recurrent thunderclap headaches and transient segmental vasoconstriction of cerebral arteries, typically resolving within 3 months ...
Ícaro Araújo de Sousa   +7 more
wiley   +1 more source

Atypical hemolytic uremic syndrome

open access: yesRenal Replacement Therapy, 2017
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure.
Yoko Yoshida   +2 more
doaj   +1 more source

Reversible Neurological Manifestations Preceding Biochemical Deterioration in Postpartum HELLP Syndrome—A Case Report and Literature Review

open access: yesThe Journal of Clinical Hypertension, Volume 28, Issue 5, May 2026.
ABSTRACT Posterior reversible encephalopathy syndrome (PRES) is a rare but severe neurological complication associated with hypertensive disorders of pregnancy and HELLP syndrome. We report a postpartum case in which neurological manifestations preceded the full biochemical expression of HELLP syndrome. A 22‐year‐old primigravida was admitted at 36 + 0
Dario Colacurci   +19 more
wiley   +1 more source

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]

open access: yes, 2015
Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael   +1 more
core   +2 more sources

Differential complement activation by alloantibodies in sickle cell hyperhaemolysis syndrome may influence disease course

open access: yes
British Journal of Haematology, EarlyView.
Mamie M. Thant   +4 more
wiley   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 688-699, April 2026.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer   +14 more
wiley   +1 more source

Clostridium septicum Infection and Hemolytic Uremic Syndrome

open access: yesEmerging Infectious Diseases, 1998
Five cases of Clostridium septicum infection secondary to Escherichia coli O157induced hemolytic uremic syndrome have been reported. We report on three cases (one of which is included in the above five) of dual Cl. septicum and E.
M. Barnham, N. Weightman
doaj   +1 more source

Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations [PDF]

open access: yes, 2013
Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are ...
Alberti, M.   +8 more
core   +1 more source

Exercise‐induced vasculitis with histological and genetic evidence of complement involvement

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Massimo Cugno   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy